Bpifrance

Maddie provides patient and practice management software solutions for physiotherapists.

Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.

Thabor Therapeutics develops innovative treatments for mucosal inflammatory diseases. They concentrated on inhibiting a new target to treat human mucosal inflammatory disorders. They also enable healthcare providers to cure their patients.

Healshape creates natural breast reconstruction solutions for all women. Healshape is a biotech startup focused on regenerative medicine.

Ribonexus is a biotech specializing in the development of new therapies to combat cancer disease. Ribonexus, whose research and development programs are focused on the treatment of melanoma, is developing a pipeline of molecules that target the eukaryotic translation Initiation Factor-4A. (eIF4A). This target is active in a wide range of solid and hematologic cancers, including melanoma, and is linked to resistance to many current treatments. Ribonexus's goal is to deliver drugs that restore sensitivity to current targeted therapies in cancer patients who have become resistant to them.

Ribonexus is a biotech specializing in the development of new therapies to combat cancer disease. Ribonexus, whose research and development programs are focused on the treatment of melanoma, is developing a pipeline of molecules that target the eukaryotic translation Initiation Factor-4A. (eIF4A). This target is active in a wide range of solid and hematologic cancers, including melanoma, and is linked to resistance to many current treatments. Ribonexus's goal is to deliver drugs that restore sensitivity to current targeted therapies in cancer patients who have become resistant to them.

SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules.

Starkage Therapeutics is a discovery-stage biotechnology company. They also provide treatment for idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunction or hepatic fibroses.

Heroic Sante is a virtual platform. They offer patients the chance to have their questions answered by qualified carers and learn from other patients. Their community works to create useful projects for patients and finances them thanks to statements on applications.

Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to its outer membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.

Fysali breaks the taboo by providing remote, non-invasive bladder monitoring. They offer superior clinical accuracy, an exceptional patient experience, and a lower cost of care. They offer remote and noninvasive bladder monitoring services.

Perha Pharmaceuticals is a biotechnology company that specializes in the research and development of kinase inhibitors. The company's investigation begins with natural marine substances. Indeed, some of the molecules optimized by Perha Pharmaceuticals' chemists and biologists are derived from natural products isolated from marine organisms.

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

Seekyo is a privately-owned biotech company that develops the next generation of chemotherapies By targeting the microenvironment of solid tumors while sparing healthy tissues, our aim is to provide treatments without adverse effects to cancer patients. Seekyo’s Smart Drugs transport potent anticancer agents in an innocuous manner toward safe tissues, provide efficient recognition of malignant specificities thanks to its targeting unit and allow the controlled release of the parent drug exclusively at the tumour site, based on its versatile enzyme-responsive self-immolative linker.

Argobio is a start-up studio devoted to developing unique therapeutic solutions, with the purpose of nurturing and launching revolutionary biotech firms. It sources cutting-edge early-stage projects from leading European academic research institutes in order to cultivate and nurture these projects before launching companies. The main focus is on rare diseases, neurological issues, oncology, and immunology. Additionally, the studio is looking to create promising platform technologies for therapeutic products.

Weliom offers digital healthcare consulting services in France.

Grapheal is a Medtech startup, which produces embedded and wearable biosensors, digital by design, minimalistic in components, with capabilities to dose biomarkers and detect pathogens anywhere with a simple smartphone. Wireless electronic biosensors produced by Grapheal are based on graphene transistors which make field diagnostics and remote patient monitoring affordable & accurate.

Fysali breaks the taboo by providing remote, non-invasive bladder monitoring. They offer superior clinical accuracy, an exceptional patient experience, and a lower cost of care. They offer remote and noninvasive bladder monitoring services.

OSE Immunotherapeutics is a biotechnology company led by immunologists focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases, and transplantation. OSE Immunotherapeutics SA is a biotechnology business that focuses on the development of immunotherapies for immune activation and modulation in immuno-oncology and autoimmune illnesses. Tedopi, OSE-172, OSE-703, FR104, and OSE-127 are among the company's products.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Honing Biosciences is a bio-therapeutics company that develops and improves cell-based therapies in particular of cancer and other chronic diseases. Cell-based approaches represent a promising avenue to develop novel therapies. Honing Biosciences leverages technologies that allow precise control of cell functions after delivery to patients, increasing the efficacy and limiting the harmful drawbacks of previous generations of treatments. Our molecular CellTuneTM technology allows to develop new classes of tunable cell therapeutics to control the dynamic delivery of proteins in patients. We can thus regulate protein expression at the cell surface or secretion of enzymes, cytokines, antibodies, adapting the delivery of therapeutic proteins to clinical evolutions. Honing Biosciences proprietary technological platform has breakthrough applications all types of cell-based therapy, including immunotherapy and reconstituting cell therapies for autoimmunity and chronic diseases.

Xenothera is a xenotherapy platform with embedded technology that renovates immunological treatments. Xenothera creates new therapeutic modes in numerous domains from immunomodulation to infectious diseases. Xenothera's technological platform is built on a double expertise of animal genetics and mastery of immunology processes. It renovates passive immunotherapy by marketing a new generation of hyperimmune polyclonal sera. Xenothera’s platform ensures short-time development thanks to their mastery of the entire process, from animal genetics, choice of the immunogen, selection, and purification of interesting immunoglobulins, and access to market authorization in accelerated timescale.

SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules.

Urania Therapeutics company is developing a unique SBDD platform for the generation of new readthrough compounds with high potential in cancer and monogenic disorders.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Customer Service meets Generative AI

ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.

ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

BioSerenity souhaite aider la communauté scientifique à mieux comprendre l'épilepsie pour mieux la soigner. Une fois anonymisées et privées de tout lien avec le patient, les données recueillies seront mise à disposition des chercheurs de l'Institut du Cerveau et de la Moelle épinière (ICM). C'est un pas décisif pour faire avancer la recherche sur l'épilepsie et améliorer le futur du diagnostic

NH TherAguix is a clinical stage company.

Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGS has had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.

Discngine provides scientific computing consulting services & solutions for Life Sciences Research. They are specialized in the integration of scientific software like BIOVIA - Accelrys Pipeline Pilot, Chemaxon, CambridgeSoft and industry standards like Oracle database or Tibco Spotfire.

TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.

Belovia has designs, manufactures and markets medical devices and equipment (electronic stocking donners, light solutions for physical mobilization, etc.).

ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.

BioSerenity souhaite aider la communauté scientifique à mieux comprendre l'épilepsie pour mieux la soigner. Une fois anonymisées et privées de tout lien avec le patient, les données recueillies seront mise à disposition des chercheurs de l'Institut du Cerveau et de la Moelle épinière (ICM). C'est un pas décisif pour faire avancer la recherche sur l'épilepsie et améliorer le futur du diagnostic

TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.

Founded in 2008, H4D has remained true to its original mission: to overcome isolation from health care, whether geographic or social, while supporting preventative medicine initiatives, as well as the treatment and the monitoring of chronic diseases. They are committed to ensuring that health checks become a straightforward and accessible recourse to everyone. Their pledge to provide health care solutions for everyone, regardless of their geographic location or social environments, coheres with Their respect or medical and paramedical professionals. H4D’s health programs are always integrated into a global health plan and are supported by systematic communication with local healthcare stakeholders.

Polywed is a Healthcare IT company developing the data-driven technology that increases in vitro fertilization (IVF) success rates. Today average IVF live birth rate is about 30%. BioChron technology doubles the efficiency of the treatment up to 60%.

Biom'Up, expert in the field of resorbable biomaterials, designs, develops and manufactures unique medical devices based on collagen technology. These innovative and clinically proven products cover many different surgical specialties - orthopaedics, spinal, cardiac, general and maxillo-facial - and improve patient healing by allowing guided regeneration of soft tissues and bone.

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

Skuldtech is specialized in the discovery of new Biomarkers and the development of Diagnostics focused on personalized medicine applications. This expertise enables the company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics associated with new treatments, especially in cancer, neurodegenerative and infectious diseases.

Nanobiotix SA develops nanomedicine programs for the treatment of cancer. The company provides NanoXray that offers a solution for cancer therapy based on a technology that is designed to allow destruction of cancer cells by inert particles. Its products include magnetic particles and laser activated nanoparticles for the treatment and diagnostic of cancer.

Nanobiotix SA develops nanomedicine programs for the treatment of cancer. The company provides NanoXray that offers a solution for cancer therapy based on a technology that is designed to allow destruction of cancer cells by inert particles. Its products include magnetic particles and laser activated nanoparticles for the treatment and diagnostic of cancer.

LINK CARE SERVICES offers clinical and pastoral counseling services and restores the whole person, mind, body, and soul. In addition, they also provide studios and one-bedroom apartments to seniors 55 years of age and older. The company's contact modes are mail, phone, and physical address.

Santen specializes in the research, development, marketing, and sales of innovative eye care products and services that enable optimal sight. They help physicians address the complex clinical challenges in vision care with novel solutions for glaucoma, retinal diseases, and other eye conditions.

Santen specializes in the research, development, marketing, and sales of innovative eye care products and services that enable optimal sight. They help physicians address the complex clinical challenges in vision care with novel solutions for glaucoma, retinal diseases, and other eye conditions.

Nanobiotix SA develops nanomedicine programs for the treatment of cancer. The company provides NanoXray that offers a solution for cancer therapy based on a technology that is designed to allow destruction of cancer cells by inert particles. Its products include magnetic particles and laser activated nanoparticles for the treatment and diagnostic of cancer.

Santen specializes in the research, development, marketing, and sales of innovative eye care products and services that enable optimal sight. They help physicians address the complex clinical challenges in vision care with novel solutions for glaucoma, retinal diseases, and other eye conditions.

Santen specializes in the research, development, marketing, and sales of innovative eye care products and services that enable optimal sight. They help physicians address the complex clinical challenges in vision care with novel solutions for glaucoma, retinal diseases, and other eye conditions.